Cytheris SA and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC), announced the selection of recombinant human interleukin-7 (CYT107), the investigational multi ... more
To use all functions of this page, please activate cookies in your browser.
